DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype

Veerle De Vriendt, Wendy De Roock, Antonio Fabio Di Narzo, Sun Tian, Bart Biesmans, Bart Jacobs, Eva Budinska, Xavier Sagaert, Simona Rossi, Giovanni D'Ario, Mauro Delorenzi, Iris Simon, Loredana Vecchione, Sabine Tejpar

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

As dual-specificity phosphatase (DUSP) expression has been correlated to sensitivity to MEK inhibitors, DUSP expression levels may indicate activation of the mitogen-activated protein kinase (MAPK) pathway in many tumor types. In this study, we investigate if DUSP levels can indicate different levels of MAPK activation within colorectal cancer (CRC) patients. In three different CRC patient microarray datasets, we analyzed the expression of DUSP1, DUSP4 and DUSP6 according to mutational status, their correlation with survival and their association with different clinical characteristics. DUSP4 was significantly differentially expressed between all mutational subgroups with the highest expression in BRAF mutated tumors. Moreover, high DUSP4 expression was associated with a worse overall survival and with clinical characteristics typical for BRAF mutant patients. The use of DUSP expression as a predictive biomarker towards MAPK targeted therapy in CRC patients needs further investigation.

Original languageEnglish
Pages (from-to)516-524
Number of pages9
JournalBiomarkers
Volume18
Issue number6
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Dual-Specificity Phosphatases
Mitogen-Activated Protein Kinases
Tumors
Colorectal Neoplasms
Chemical activation
Genotype
Survival
Mitogen-Activated Protein Kinase Kinases
Biomarkers
Microarrays
Neoplasms
Association reactions

Keywords

  • Colorectal cancer
  • gene expression
  • MAPK pathway

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Health, Toxicology and Mutagenesis

Cite this

De Vriendt, V., De Roock, W., Di Narzo, A. F., Tian, S., Biesmans, B., Jacobs, B., ... Tejpar, S. (2013). DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype. Biomarkers, 18(6), 516-524. https://doi.org/10.3109/1354750X.2013.819038

DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype. / De Vriendt, Veerle; De Roock, Wendy; Di Narzo, Antonio Fabio; Tian, Sun; Biesmans, Bart; Jacobs, Bart; Budinska, Eva; Sagaert, Xavier; Rossi, Simona; D'Ario, Giovanni; Delorenzi, Mauro; Simon, Iris; Vecchione, Loredana; Tejpar, Sabine.

In: Biomarkers, Vol. 18, No. 6, 09.2013, p. 516-524.

Research output: Contribution to journalArticle

De Vriendt, V, De Roock, W, Di Narzo, AF, Tian, S, Biesmans, B, Jacobs, B, Budinska, E, Sagaert, X, Rossi, S, D'Ario, G, Delorenzi, M, Simon, I, Vecchione, L & Tejpar, S 2013, 'DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype', Biomarkers, vol. 18, no. 6, pp. 516-524. https://doi.org/10.3109/1354750X.2013.819038
De Vriendt, Veerle ; De Roock, Wendy ; Di Narzo, Antonio Fabio ; Tian, Sun ; Biesmans, Bart ; Jacobs, Bart ; Budinska, Eva ; Sagaert, Xavier ; Rossi, Simona ; D'Ario, Giovanni ; Delorenzi, Mauro ; Simon, Iris ; Vecchione, Loredana ; Tejpar, Sabine. / DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype. In: Biomarkers. 2013 ; Vol. 18, No. 6. pp. 516-524.
@article{4203adfedcbe4aab8d972e0d7d051a5d,
title = "DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype",
abstract = "As dual-specificity phosphatase (DUSP) expression has been correlated to sensitivity to MEK inhibitors, DUSP expression levels may indicate activation of the mitogen-activated protein kinase (MAPK) pathway in many tumor types. In this study, we investigate if DUSP levels can indicate different levels of MAPK activation within colorectal cancer (CRC) patients. In three different CRC patient microarray datasets, we analyzed the expression of DUSP1, DUSP4 and DUSP6 according to mutational status, their correlation with survival and their association with different clinical characteristics. DUSP4 was significantly differentially expressed between all mutational subgroups with the highest expression in BRAF mutated tumors. Moreover, high DUSP4 expression was associated with a worse overall survival and with clinical characteristics typical for BRAF mutant patients. The use of DUSP expression as a predictive biomarker towards MAPK targeted therapy in CRC patients needs further investigation.",
keywords = "Colorectal cancer, gene expression, MAPK pathway",
author = "{De Vriendt}, Veerle and {De Roock}, Wendy and {Di Narzo}, {Antonio Fabio} and Sun Tian and Bart Biesmans and Bart Jacobs and Eva Budinska and Xavier Sagaert and Simona Rossi and Giovanni D'Ario and Mauro Delorenzi and Iris Simon and Loredana Vecchione and Sabine Tejpar",
year = "2013",
month = "9",
doi = "10.3109/1354750X.2013.819038",
language = "English",
volume = "18",
pages = "516--524",
journal = "Biomarkers",
issn = "1354-750X",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype

AU - De Vriendt, Veerle

AU - De Roock, Wendy

AU - Di Narzo, Antonio Fabio

AU - Tian, Sun

AU - Biesmans, Bart

AU - Jacobs, Bart

AU - Budinska, Eva

AU - Sagaert, Xavier

AU - Rossi, Simona

AU - D'Ario, Giovanni

AU - Delorenzi, Mauro

AU - Simon, Iris

AU - Vecchione, Loredana

AU - Tejpar, Sabine

PY - 2013/9

Y1 - 2013/9

N2 - As dual-specificity phosphatase (DUSP) expression has been correlated to sensitivity to MEK inhibitors, DUSP expression levels may indicate activation of the mitogen-activated protein kinase (MAPK) pathway in many tumor types. In this study, we investigate if DUSP levels can indicate different levels of MAPK activation within colorectal cancer (CRC) patients. In three different CRC patient microarray datasets, we analyzed the expression of DUSP1, DUSP4 and DUSP6 according to mutational status, their correlation with survival and their association with different clinical characteristics. DUSP4 was significantly differentially expressed between all mutational subgroups with the highest expression in BRAF mutated tumors. Moreover, high DUSP4 expression was associated with a worse overall survival and with clinical characteristics typical for BRAF mutant patients. The use of DUSP expression as a predictive biomarker towards MAPK targeted therapy in CRC patients needs further investigation.

AB - As dual-specificity phosphatase (DUSP) expression has been correlated to sensitivity to MEK inhibitors, DUSP expression levels may indicate activation of the mitogen-activated protein kinase (MAPK) pathway in many tumor types. In this study, we investigate if DUSP levels can indicate different levels of MAPK activation within colorectal cancer (CRC) patients. In three different CRC patient microarray datasets, we analyzed the expression of DUSP1, DUSP4 and DUSP6 according to mutational status, their correlation with survival and their association with different clinical characteristics. DUSP4 was significantly differentially expressed between all mutational subgroups with the highest expression in BRAF mutated tumors. Moreover, high DUSP4 expression was associated with a worse overall survival and with clinical characteristics typical for BRAF mutant patients. The use of DUSP expression as a predictive biomarker towards MAPK targeted therapy in CRC patients needs further investigation.

KW - Colorectal cancer

KW - gene expression

KW - MAPK pathway

UR - http://www.scopus.com/inward/record.url?scp=84885204398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885204398&partnerID=8YFLogxK

U2 - 10.3109/1354750X.2013.819038

DO - 10.3109/1354750X.2013.819038

M3 - Article

C2 - 23875912

AN - SCOPUS:84885204398

VL - 18

SP - 516

EP - 524

JO - Biomarkers

JF - Biomarkers

SN - 1354-750X

IS - 6

ER -